Verona Pharma Plc ADR (VRNA)

$106.91 +0.12 (0.11%)
Market Cap 8.75B
Revenue (ttm) 42.28M
Net Income (ttm) -173.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 872.73
Profit Margin -410.17%
Debt to Equity Ratio 0.87
Volume 1,871,900
Avg Vol 1,571,794
Day's Range N/A - N/A
Shares Out 81.83M
Stochastic %K 97%
Beta 0.05
Analysts Sell
Price Target $106.00

Company Profile

Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was formerly known as Isis...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 20 3283 4200
Address:
3 More London Riverside, London, United Kingdom
JFais
JFais Jun. 14 at 2:07 PM
$VRNA - still can't believe I missed this one, but the W is applied learnings to $LQDA early launch metrics & bought in full-size. For each setback or missed opportunity, seek to turn the Loss into a Win by learning from it & apply going forward 👍
0 · Reply
rotehefe
rotehefe Jun. 8 at 8:34 PM
$CADL tik-tok tik-tok; another day passed by, free float gets reduced constantly and every day passes by we are one day closer to fantastic news. And then I would not like to be in the shoes of the short guys... keep strong hand with your shares, I see a big reward, remembers me to $VRNA
0 · Reply
De12
De12 May. 22 at 5:33 PM
$OLMA Druck had buyouts with $CDTX , $SWTX And $VRNA , Next is $OLMA Squeeeze!!
0 · Reply
stjernerogvann
stjernerogvann May. 19 at 2:32 PM
$SLS @yG19 is not wrong about these opportunities coming along so seldom. I got lucky that @Trainguy1 brought $VRNA to my attention - that was a no-brainer, too. But this one seems even more so... Getting this much insight into how a trial is going is rare. I hope that many retail people take advantage - at least in a small way.
1 · Reply
ShadowBull3745
ShadowBull3745 May. 15 at 6:48 PM
$CADL $CCXI $VRNA
0 · Reply
marked0ne
marked0ne May. 15 at 6:40 PM
$CADL i've been into a few awesome investor calls over the last few years ($VRNA , $CCXI) . But this is the best investors call i've heard. ever.
3 · Reply
Kingjake26
Kingjake26 May. 15 at 5:54 PM
$CADL Been part of several buyouts. I’m not sure what will happen here. Buyout or go on own but this is a multi billion dollar opportunity. I was part of big buyouts. $VRNA $MYOV CCXI. And a few others. Plus I own $CAPR with over 500% gain. Just a major opportunity My two two investments are CADL and CAPR
4 · Reply
marked0ne
marked0ne May. 15 at 5:35 PM
$CADL damn, i really thought my position was big enough. But damn, my belly tells me BUY BUY BUY! I get some serious $VRNA vibes here!
1 · Reply
TwongStocks
TwongStocks May. 12 at 11:44 AM
$VRNA Some former VRNA execs join ACHV https://www.globenewswire.com/news-release/2026/05/12/3292696/0/en/achieve-life-sciences-strengthens-board-and-commercial-leadership-with-three-senior-appointments-from-team-previously-at-verona-pharma.html Christopher Martin (former VRNA CCO) joined the Board of Directors. Mark Zappia joined as Senior Vice President, Commercial. He oversaw the commercial strategy for Ohtuvayre Jim Willis joined as Vice President of Sales and Sales Enablement. He led the Ohtuvayre national field force. “Bringing Chris, Mark, and Jim to Achieve is one of the most consequential decisions of my first month as CEO and reflects our evolution into a commercial-stage organization,” said Andrew D. Goldberg, MD, Chief Executive Officer of Achieve Life Sciences. “Having anchored Verona Pharma’s U.S. market transition, I saw firsthand the discipline and excellence this team brings to a commercial launch. We are addressing one of the largest preventable public health problems we know, and the experience this team brings positions Achieve to deliver cytisinicline to the patients who need it and the prescribers who care for them.”
0 · Reply
BigCh33z3
BigCh33z3 May. 10 at 12:26 PM
$VRNA I said BTFD ¯\_(ツ)_/¯
0 · Reply
Latest News on VRNA
No data available.
JFais
JFais Jun. 14 at 2:07 PM
$VRNA - still can't believe I missed this one, but the W is applied learnings to $LQDA early launch metrics & bought in full-size. For each setback or missed opportunity, seek to turn the Loss into a Win by learning from it & apply going forward 👍
0 · Reply
rotehefe
rotehefe Jun. 8 at 8:34 PM
$CADL tik-tok tik-tok; another day passed by, free float gets reduced constantly and every day passes by we are one day closer to fantastic news. And then I would not like to be in the shoes of the short guys... keep strong hand with your shares, I see a big reward, remembers me to $VRNA
0 · Reply
De12
De12 May. 22 at 5:33 PM
$OLMA Druck had buyouts with $CDTX , $SWTX And $VRNA , Next is $OLMA Squeeeze!!
0 · Reply
stjernerogvann
stjernerogvann May. 19 at 2:32 PM
$SLS @yG19 is not wrong about these opportunities coming along so seldom. I got lucky that @Trainguy1 brought $VRNA to my attention - that was a no-brainer, too. But this one seems even more so... Getting this much insight into how a trial is going is rare. I hope that many retail people take advantage - at least in a small way.
1 · Reply
ShadowBull3745
ShadowBull3745 May. 15 at 6:48 PM
$CADL $CCXI $VRNA
0 · Reply
marked0ne
marked0ne May. 15 at 6:40 PM
$CADL i've been into a few awesome investor calls over the last few years ($VRNA , $CCXI) . But this is the best investors call i've heard. ever.
3 · Reply
Kingjake26
Kingjake26 May. 15 at 5:54 PM
$CADL Been part of several buyouts. I’m not sure what will happen here. Buyout or go on own but this is a multi billion dollar opportunity. I was part of big buyouts. $VRNA $MYOV CCXI. And a few others. Plus I own $CAPR with over 500% gain. Just a major opportunity My two two investments are CADL and CAPR
4 · Reply
marked0ne
marked0ne May. 15 at 5:35 PM
$CADL damn, i really thought my position was big enough. But damn, my belly tells me BUY BUY BUY! I get some serious $VRNA vibes here!
1 · Reply
TwongStocks
TwongStocks May. 12 at 11:44 AM
$VRNA Some former VRNA execs join ACHV https://www.globenewswire.com/news-release/2026/05/12/3292696/0/en/achieve-life-sciences-strengthens-board-and-commercial-leadership-with-three-senior-appointments-from-team-previously-at-verona-pharma.html Christopher Martin (former VRNA CCO) joined the Board of Directors. Mark Zappia joined as Senior Vice President, Commercial. He oversaw the commercial strategy for Ohtuvayre Jim Willis joined as Vice President of Sales and Sales Enablement. He led the Ohtuvayre national field force. “Bringing Chris, Mark, and Jim to Achieve is one of the most consequential decisions of my first month as CEO and reflects our evolution into a commercial-stage organization,” said Andrew D. Goldberg, MD, Chief Executive Officer of Achieve Life Sciences. “Having anchored Verona Pharma’s U.S. market transition, I saw firsthand the discipline and excellence this team brings to a commercial launch. We are addressing one of the largest preventable public health problems we know, and the experience this team brings positions Achieve to deliver cytisinicline to the patients who need it and the prescribers who care for them.”
0 · Reply
BigCh33z3
BigCh33z3 May. 10 at 12:26 PM
$VRNA I said BTFD ¯\_(ツ)_/¯
0 · Reply
BioStick123
BioStick123 May. 7 at 7:20 PM
$URGN $XBI $VRNA
0 · Reply
shopno
shopno May. 7 at 5:41 PM
$IOVA while I am pessimistic with management, specially the clown interim CEO, >=40% YoY growth for cell therapy is considered healthy / remarkable. $IOVA is not $MDGL or $VRNA — that investors should have expected >= 100% YoY growth at end of 2nd year of launch. That being said, upside till H1 2027 is very limited. Cheap options for 20027 may give some return if stock jumps $6-8 later this year with >= 40% YoY growth and >= 50% gross.
0 · Reply
shopno
shopno May. 6 at 4:16 PM
$MDGL while the management fake hypes on 50% patients expansion for F2/F3 MASH, incremental patients declined QoQ. Last Quarter added ~7k patients, this quarter only 6k. While I invested both in $VRNA and $MDGL , the latter has been too poor performing in comparison — up only ~70% since fda approval while TTM revenue > $1.1B.
1 · Reply
Kingjake26
Kingjake26 Apr. 29 at 12:19 PM
$CADL I love what our CEO is doing is is building a strong business. Every day that goes buy it will cost large pharma more and more if they want this. The best part is if they don’t we will grow organically and be a multibillion dollar company in my opinion. This reminds me of $VRNA amazing management team
0 · Reply
De12
De12 Apr. 24 at 5:33 PM
$ADMA $CDTX $SWTX $VRNA $ADMA it’s Next!!
0 · Reply
BullriderNkg
BullriderNkg Apr. 23 at 8:41 AM
$VRNA As most Bulls miss OUR Verona . I just checked Q4 sales of Ohtuvayre 2025 for Merck were 178 Million. So 2026 it would have been a Billion dollar drug. I said it before management sold it too soon. Probably some big bonuses!!!
2 · Reply
De12
De12 Apr. 14 at 11:16 PM
$ADMA Druckenmiller had buyouts with $CDTX $SWTX $VRNA and Next will be $ADMA load Up!!
2 · Reply
De12
De12 Apr. 2 at 2:05 PM
$ADMA Druckenmiller had Buyouts with $VRNA $CDTX $SWTX next is $ADMA
1 · Reply
YungBullHOLLA
YungBullHOLLA Mar. 31 at 1:07 PM
$VRNA have a good rest of the week ol friends
0 · Reply
moneybag888
moneybag888 Mar. 27 at 5:00 PM
$DNLI $45 to $65 buyout dejavu $VRNA
0 · Reply
LongLongStock
LongLongStock Mar. 24 at 8:05 AM
$VRNA I miss this stock
2 · Reply
YungBullHOLLA
YungBullHOLLA Mar. 21 at 3:17 PM
$VRNA Miss you guys
2 · Reply